More recently, two independent groups reported that myostatin could be a quantifiable biomarker to monitor drug response in several neuromuscular diseases including Duchenne muscular dystrophy [99] and myotubular myopathy [100]. This evidence concerns the gene MSTN and neuromuscular disease.